Day One Biopharmaceuticals, Inc. (DAWN) Stock Analysis & Investment Frameworks
Day One Biopharmaceuticals, Inc. (DAWN) stock analysis on Invetso. Review Day One Biopharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Day One Biopharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Day One Biopharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $2.22B
- Revenue: $158.18M
- ROE: -15.82%
- ROIC: -18.85%
- Dividend Yield: N/A
About Day One Biopharmaceuticals, Inc.
Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma. Additionally, the company is advancing Pimasertib, an oral small molecule designed to inhibit mitogen-activated protein kinase kinases 1 and 2. Established in 2018, Day One Biopharmaceuticals, Inc. maintains its primary operations in South San Francisco, California.